Latest filing published 16 Jun 2026 for Tarsus Pharmaceuticals, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Bhaskar Chaudhuri (board member) discloses dealings in 2 companies, chiefly Arcutis Biotherapeutics, Inc. and Tarsus Pharmaceuticals, Inc. In total, 12 filings cover trades dated from 20 April 2021 to 12 June 2026.
No open-market purchase appears, only 4 sales worth €503k. Besides market trades, the filings include 4 share grants and 4 option exercises.
The latest filing, published on 16 June 2026, reports an option exercise in Tarsus Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations